Anti-CD19 scFv (FMC63) polypeptide
Provided are monoclonal antibodies that detect CD 19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells.
1. An isolated antibody or antibody fragment thereof, that specifically binds to a CD19-specific scFv (FMC63) chimeric antigen receptor (CAR) polypeptide, wherein the isolated antibody or antibody fragment comprises a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein
(a) HCDR1 has the amino acid sequence of SEQ ID NO: 2;
(b) HCDR2 has the amino acid sequence of SEQ ID NO: 3;
(c) HCDR3 has the amino acid sequence of SEQ ID NO: 4;
(d) LCDR1 has the amino acid sequence of SEQ ID NO: 6;
(e) LCDR2 has the amino acid sequence of SEQ ID NO: 7; and
(f) LCDR3 has the amino acid sequence of SEQ ID NO: 8.
2. An isolated antibody or antibody fragment thereof that specifically binds to a CD19-specific scFv (FMC63) chimeric antigen receptor (CAR) polypeptide, wherein the isolated antibody or antibody fragment comprises a heavy chain variable region (VH) having the amino acid sequence of SEQ ID NO: 1, and a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 5.
3. A pharmaceutical composition comprising the antibody or antibody fragment thereof of claim 1 .
4. A pharmaceutical composition comprising the antibody or antibody fragment thereof of claim 2 .
5. The isolated antibody or antibody fragment thereof of claim 1 , wherein the antibody or antibody fragment thereof is conjugated to a toxin.
6. The isolated antibody or antibody fragment thereof of claim 2 , wherein the antibody or antibody fragment thereof is conjugated to a toxin.